NEW YORK (AP) — A major generic drugmaker has paid Bristol-Myers Squibb Co. and Sanofi SA more than $445 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.
Apotex Corp., Canada's biggest drugmaker, has paid the two brand-name drugmakers $442.2 million in damages for selling a generic version of Plavix in 2006.
Apotex launched its copycat version while it was still in a court dispute with Bristol and Sanofi, partners who jointly market Plavix. Apotex argued at the time that key patents on Plavix were invalid, doing what's called an "at-risk launch" of its generic version of Plavix.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
